Loading...

Pipeline

Our pipeline

Our lead molecule Lynflexine™ is a first-in-class drug candidate with disease modifying potential for the treatment of relapsing remitting and progressive forms of multiple sclerosis and for the treatment of neurodegeneration following concussion. Phase 2a studies in acute relapse in MS and concussion to be initiated in 2023.

Lynflexine™ is a recombinant Human Relaxin 2 in a nasal spray, ready for phase II. Relaxin (RLN) is a peptide hormone structurally related to insulin. The relaxin peptide superfamily is up- regulated in pregnancy – when MS improves.

RLN is pleiotropic in nature, acting as an agonist for the glucocorticoid receptor (GCR) and the relaxin family peptide receptors 1 and 2.

Strong Intellectual Property

MECHANISM OF ACTION

Through the glucocorticoid receptor and the relaxin family peptide receptors 1 and 2, relaxin can modulate the immune system by suppressing cell adhesion molecules, increasing cyclic adenosine monophosphate, regulating differential expression of matrix metalloproteinases, regulating cytokine and chemokine receptor (CCR) expression and inhibit cell-mediated pro-inflammatory activity by stimulation of the peroxisome proliferator-activated receptor gamma (PPARγ), which has neuroprotective effects. Through these diverse actions, RLN has the potential to modulate the clinical symptoms of MS, be neuroprotective and promote remyelination.

BVBiomed is a research driven company dedicated to the discovery of novel therapeutic compounds for use in treating neuro-degenerative diseases. We are currently developing two new compounds which are anti-inflammatory and auto-immune regulators and are preparing clinical trials of these therapies in treating multiple sclerosis.

Contacts
  • Address
    Magdalen Centre, The Oxford Science Park, Robert Robinson Drive, Oxford, Oxfordshire OX4 4GA, U.K.
  • Phone
  • +44 1865 784 062
  • E-mail
    info [at] bvbiomed . com
    (remove spaces between words)